Skip to content

Enhanced Trofile assay better at identifying HIV tropisms, only slight impact on virologic outcomes

Tenofovir/FTC more effective than abacavir/3TC in first-line boosted-PI regimens: meta-analysis

Start treatment at CD4 cell counts below 500, says large cohort study

No significant differences between elvucitabine and 3TC at 48 weeks

Raltegravir non-inferior to efavirenz: 48 week, phase III results

Is there a role for tropism testing in routine HIV care?

Once-daily darunavir (Prezista) approved for first-line use in United States

Low rate of spontaneous hepatitis C clearance in patients with HIV; early HIV treatment recommended for those with chronic hepatitis C infection

Hypersensitivity testing for abacavir slightly more cost-effective than tenofovir use, if both drugs equally potent